3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
Sarcoma
2
Head & Neck
2
Breast
2
Thoracic
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Ovarian Neoplasms
27
Fallopian Tube Neoplasms
24
Uterine Cervical Neoplasms
7
Brenner Tumor
6
Endometrial Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Melanoma
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Endometrial Adenocarcinoma
2
Cervical Adenocarcinoma
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Neoplasms
1
Stomach Neoplasms
1
Somatostatinoma
1
Sertoli-Leydig Cell Tumor
1
Sarcoma
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrence
1
Interventions
pembrolizumab
24
Nivolumab
15
Magnetic Resonance Spectroscopy
7
Ipilimumab
6
avelumab
5
atezolizumab
5
Specimen Handling
5
Docetaxel
4
lenvatinib
3
durvalumab
3
Paclitaxel
3
Cyclophosphamide
3
Carboplatin
3
fludarabine
2
cabozantinib
2
aldesleukin
2
Interleukin-2
2
Fluorodeoxyglucose F18
2
FAPI-46
2
zanidatamab
1
veliparib
1
tislelizumab
1
spartalizumab
1
soluble LAG-3 protein, human
1
sargramostim
1
sacituzumab govitecan
1
rucaparib
1
regorafenib
1
poly ICLC
1
olaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Immunoglobulin G
×
Gynecologic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled